Skip to main content
CELC
NASDAQ Industrial Applications And Services

Celcuity 10-Q: $642.7M Cash Through 2029, Q3 Loss Widens to $73.3M on Launch Costs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$64.04
Mkt Cap
$3.134B
52W Low
$53.54
52W High
$151.02
52W Position info
20% above low
Off High info
58% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CELC sits 20% above its 52-week low of $53.54.

Summary

Celcuity's Q3 net loss widened to $73.3 million ($1.33/share) on a 220% jump in launch-related SG&A, with no product revenue yet since REVTORPYK shipments began September 30. Cash and investments of $642.7 million are expected to fund operations through 2029.


Key Events · Earnings and Guidance · CELC

  • Q3 Loss Widens on Launch Spending

    Net loss was $73.3 million ($1.33 per share) versus $43.8 million a year earlier, driven by SG&A of $39.8 million, up 220% from $12.4 million.

  • No Product Revenue Yet

    REVTORPYK shipments began September 30, 2026, so no product was received by providers before quarter-end and no revenue was recognized; inventory of $1.476 million was capitalized for the first time.

  • Cash Runway Through 2029

    Cash, cash equivalents and short-term investments totaled $642.7 million at September 30, 2026, which management expects to fund planned operations through 2029.

  • Convertible Notes Refinanced

    The June 2026 offering of $575.0 million principal 0.250% notes due 2032 raised $557.0 million net; $137.4 million repaid the Oxford/Innovatus loan, producing an $11.5 million non-cash loss on extinguishment.


Analysis · CELC · Industrial Applications And Services

The cost of the REVTORPYK launch is now visible: in Celcuity's first full quarter as a commercial company, SG&A jumped 220% to $39.8 million and the net loss widened to $73.3 million ($1.33 per share) from $43.8 million a year earlier. No product revenue was booked because shipments only began September 30, 2026, so the first real sales number lands in Q4. Against that spending, the balance sheet is the story — $642.7 million in cash and short-term investments, which management says funds operations through 2029, after the June 2026 convertible notes raised $557.0 million net and retired the Oxford/Innovatus term loan at an $11.5 million non-cash extinguishment loss. The next hard data point is Q4 revenue, the first period that will show whether the launch is converting patients into sales.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELC was trading at $64.04 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $53.54 to $151.02. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $53.35 info
Change: -$12.97 (-20%) info
Market Cap: $2.621B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $53.35 info
Change: -$10.69 (-17%) info
Market Cap: $2.621B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $53.35 info
Change: -$10.69 (-17%) info
Market Cap: $2.621B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $53.35 info
Change: -$25.65 (-32%) info
Market Cap: $2.621B info
CELC
Aug 26, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $91.00
Real-time Price: $53.35 info
Change: -$37.65 (-41%) info
Market Cap: $2.621B info